Literature DB >> 17654743

A lipidomic analysis of nonalcoholic fatty liver disease.

Puneet Puri1, Rebecca A Baillie, Michelle M Wiest, Faridoddin Mirshahi, Jayanta Choudhury, Onpan Cheung, Carol Sargeant, Melissa J Contos, Arun J Sanyal.   

Abstract

UNLABELLED: The spectrum of nonalcoholic fatty liver disease (NAFLD) includes a nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). The specific types and amounts of lipids that accumulate in NAFLD are not fully defined. The free fatty acid (FFA), diacylglycerol (DAG), triacylglycerol (TAG), free cholesterol (FC), cholesterol ester, and phospholipid contents in normal livers were quantified and compared to those of NAFL and NASH, and the distribution of fatty acids within these classes was compared across these groups. Hepatic lipids were quantified by capillary gas chromatography. The mean (nmol/g of tissue) DAG (normal/NAFL/NASH: 1922 versus 4947 versus 3304) and TAG (13,609 versus 128,585 versus 104,036) increased significantly in NAFLD, but FFA remained unaltered (5533 versus 5929 versus 6115). There was a stepwise increase in the mean TAG/DAG ratio from normal livers to NAFL to NASH (7 versus 26 versus 31, P < 0.001). There was also a similar stepwise increment in hepatic FC (7539 versus 10,383 versus 12,863, P < 0.05 for NASH). The total phosphatidylcholine (PC) decreased in both NAFL and NASH. The FC/PC ratio increased progressively (0.34 versus 0.69 versus 0.71, P < 0.008 for both). Although the levels for linoleic acid (18:2n-6) and alpha-linolenic acid (18:3n-3) remained unaltered, there was a decrease in arachidonic acid (20:4n-6) in FFA, TAG, and PC (P < 0.05 for all) in NASH. Eicosapentanoic acid (20:5n-3) and docosahexanoic acid (22:6n-3) were decreased in TAG in NASH. The n-6:n-3 FFA ratio increased in NASH (P < 0.05).
CONCLUSIONS: NAFLD is associated with numerous changes in the lipid composition of the liver. The potential implications are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654743     DOI: 10.1002/hep.21763

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  421 in total

1.  Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis.

Authors:  Hussam Alamri; Nathan Heath Patterson; Ethan Yang; Pablo Zoroquiain; Anthoula Lazaris; Pierre Chaurand; Peter Metrakos
Journal:  Anal Bioanal Chem       Date:  2018-12-05       Impact factor: 4.142

2.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

3.  Plasma metabolomic profile in nonalcoholic fatty liver disease.

Authors:  Satish C Kalhan; Lining Guo; John Edmison; Srinivasan Dasarathy; Arthur J McCullough; Richard W Hanson; Mike Milburn
Journal:  Metabolism       Date:  2010-04-27       Impact factor: 8.694

4.  CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis.

Authors:  Sophie C Cazanave; Nafisa A Elmi; Yuko Akazawa; Steven F Bronk; Justin L Mott; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

5.  Challenging the rodent hegemony: a new rabbit model of nonalcoholic steatohepatitis.

Authors:  Jaideep Behari; Naga Chalasani
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

6.  Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.

Authors:  Anisha A Gupte; Joey Z Liu; Yuelan Ren; Laurie J Minze; Jessica R Wiles; Alan R Collins; Christopher J Lyon; Domenico Pratico; Milton J Finegold; Stephen T Wong; Paul Webb; John D Baxter; David D Moore; Willa A Hsueh
Journal:  Hepatology       Date:  2010-10-11       Impact factor: 17.425

Review 7.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 8.  Modulation of hepatic steatosis by dietary fatty acids.

Authors:  Alessandra Ferramosca; Vincenzo Zara
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.

Authors:  Bruno Ramos-Molina; Daniel Castellano-Castillo; Oscar Pastor; Luis Ocaña-Wilhelmi; Diego Fernández-García; Manuel Romero-Gómez; Fernando Cardona; Francisco J Tinahones
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 10.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.